Watching how focused radiation works for melanoma that has spread to the brain
Official title: MELanoma Brain Metastasis Treated With CYberknife
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study follows people with melanoma in the brain who get a very precise kind of radiation.
Read our full plain-language summary
What the trial team says
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life. In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma. This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes. Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
Key facts
- Registry number
- NCT07691255
- Conditions studied
- Melanoma (Skin Cancer)
Where it is running
This trial lists 2 sites.
-
Italy
- European Institute of Oncology, Milan (Milan)
-
Mi
- European Institute of Oncology, Milan (Milan)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.